Stayble Therapeutics

Stayble Therapeutics is a focused, clinical-stage company dedicated to developing STA363, a unique intradiscal injection for chronic pain from lumbar disc herniation (LDH). Its mission is to provide a simple, effective therapeutic option for millions of patients for whom pain medication and physiotherapy have failed, potentially avoiding the need for major surgery. The company's strategy hinges on successfully navigating clinical trials for STA363 to establish it as a leading second-line, minimally invasive treatment. Currently in Phase 1b, Stayble is pre-revenue, with its value and prospects intrinsically tied to the clinical and future commercial success of its singular asset.

Proprietary platform for developing a unique, minimally invasive intradiscal injection therapy designed to treat lumbar disc herniation at the source, aiming for localized disease modification or sustained pain relief.

Competes against entrenched standards of care: first-line pain medications/physiotherapy, epidural steroid injections, and ultimately spinal surgery. Few direct pharmaceutical competitors exist for localized intradiscal treatment, but must demonstrate superior efficacy to steroids and a favorable risk-benefit profile compared to surgery.